Dahong Yu
Overview
Explore the profile of Dahong Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
988
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ezzedine K, Peeva E, Yamaguchi Y, Cox L, Banerjee A, Han G, et al.
J Am Acad Dermatol
. 2022 Nov;
88(2):395-403.
PMID: 36370907
Background: Vitiligo is a chronic autoimmune disorder characterized by depigmented patches of the skin. Objective: To evaluate the efficacy and safety of ritlecitinib, an oral JAK3 (Janus kinase)/TEC (tyrosine kinase...
2.
Wang Y, Tong L, Gu N, Ma X, Lu D, Yu D, et al.
J Diabetes Res
. 2022 Apr;
2022:8494502.
PMID: 35469171
Aims: To explore the associations between polymorphisms in SIRT1 and coronary heart disease (CHD) risk in Chinese Han patients with type 2 diabetes (T2D). Methods: This case-controlled study enrolled 492...
3.
Forman S, Pariser D, Poulin Y, Vincent M, Gilbert S, Kieras E, et al.
J Invest Dermatol
. 2020 Apr;
140(12):2359-2370.e5.
PMID: 32311398
Trial Design: We report results from a phase IIa study of efficacy and safety of PF-06700841, an oral TYK2/Jak1 inhibitor, in patients with moderate-to-severe plaque psoriasis (NCT02969018). Methods: Patients were...
4.
Sandborn W, Su C, Sands B, DHaens G, Vermeire S, Schreiber S, et al.
N Engl J Med
. 2017 May;
376(18):1723-1736.
PMID: 28467869
Background: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy...
5.
Sandborn W, Panes J, Zhang H, Yu D, Niezychowski W, Su C
Gastroenterology
. 2015 Sep;
150(1):96-102.
PMID: 26376350
Background & Aims: Accurate biomarkers of disease activity and therapeutic response can be valuable for clinical trials. We performed a post hoc analysis of data from a phase 2 trial...
6.
Michna E, Weil A, Duerden M, Schulman S, Wang W, Tzanis E, et al.
Pain Med
. 2011 Aug;
12(8):1223-30.
PMID: 21810165
Objective: Methylnaltrexone, a selective peripherally acting mu-opioid receptor antagonist, effectively treats opioid-induced constipation (OIC) in patients with advanced illness and shows efficacy in patients with chronic nonmalignant pain. The objective...
7.
Kahn S, Haffner S, Viberti G, Herman W, Lachin J, Kravitz B, et al.
Diabetes Care
. 2009 Oct;
33(1):177-83.
PMID: 19808911
Objective: C-reactive protein (CRP) is closely associated with obesity and cardiovascular disease in both diabetic and nondiabetic populations. In the short term, commonly prescribed antidiabetic agents have different effects on...
8.
Kahn S, Zinman B, Lachin J, Haffner S, Herman W, Holman R, et al.
Diabetes Care
. 2008 Jan;
31(5):845-51.
PMID: 18223031
Objective: The purpose of this study was to examine possible factors associated with the increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression Trial (ADOPT). Research Design...
9.
Hollander P, Yu D, Chou H
Arch Intern Med
. 2007 Jun;
167(12):1284-90.
PMID: 17592102
Background: The objective was to compare the efficacy and safety of adding low-dose rosiglitazone (2 or 4 mg/d) to insulin therapy vs continued insulin monotherapy in patients with type 2...
10.
Yu D, Murdoch S, Parikh S, Marcovina S, Cobitz A, Chen H, et al.
Diab Vasc Dis Res
. 2006 Dec;
3(3):189-96.
PMID: 17160915
A substantial number of individuals with type 2 diabetes mellitus (T2DM) demonstrate a predominance of small dense low-density lipoprotein (sdLDL), which is associated with an increased risk of cardiovascular disease...